High levels of microRNA-155 (miR-155) are associated with poor outcome in acute myeloid leukemia (AML). In AML, miR-155 is regulated by NF-κB, the activity of which is, in part, controlled by the NEDD8-dependent ubiquitin ligases. We demonstrate that MLN4924, an inhibitor of NEDD8-activating enzyme presently being evaluated in clinical trials, decreases binding of NF-κB to the miR-155 promoter and downregulates miR-155 in AML cells. This results in the upregulation of the miR-155 targets SHIP1, an inhibitor of the PI3K/Akt pathway, and PU.1, a transcription factor important for myeloid differentiation, leading to monocytic differentiation and apoptosis. Consistent with these results, overexpression of miR-155 diminishes MLN4924-induced antileukemic effects. In vivo, MLN4924 reduces miR-155 expression and prolongs the survival of mice engrafted with leukemic cells. Our study demonstrates the potential of miR-155 as a novel therapeutic target in AML via pharmacologic interference with NF-κB-dependent regulatory mechanisms. We show the targeting of this oncogenic microRNA with MLN4924, a compound presently being evaluated in clinical trials in AML. As high miR-155 levels have been consistently associated with aggressive clinical phenotypes, our work opens new avenues for microRNA-targeting therapeutic approaches to leukemia and cancer patients. Inhibition of neddylation in AML targets miR-155 J Khalife et al Inhibition of neddylation in AML targets miR-155 J Khalife et al Inhibition of neddylation in AML targets miR-155 J Khalife et al
INTRODUCTION
Acute myeloid leukemia (AML) is a malignant disease of the hematopoietic system characterized by maturation arrest and hyperproliferation of clonal myeloid precursors. Standard treatment for AML generally consists of cytarabine/anthracycline-based chemotherapy; however, only a minority of patients are cured with this approach. 1 More intensive treatments, including allogeneic stem cell transplantation, albeit more effective, often results in increased toxicity and treatment-related mortality. Thus, novel therapies are urgently needed.
microRNA-155 (miR-155) is a noncoding RNA frequently deregulated in cancer and leukemia and its upregulation has been associated with more aggressive disease 2 and chemoresistance. 3 In AML, high expression of miR-155 independently predicts poor outcome in cytogenetically normal patients 4 and is associated with high-risk FLT3 internal tandem duplication (ITD) mutations. 5 Ectopic expression of miR-155 in hematopoietic progenitors can induce either a myeloproliferative disorder, 6 or an aggressive B-cell leukemia in mice, 7 supporting a leukemogenic role of miR-155. Furthermore, miR-155 overexpression in human CD34+ progenitors perturbs normal myeloid and erythroid differentiation. 8 Among the downstream targets of miR-155, relevant to normal and clinical hematopoiesis, are the Src homology-2 domain-containing inositol 5-phosphatase 1 (SHIP1) tumor suppressor 9 and PU.1, 10,11 a transcription factor critical for myelomonocytic differentiation. 12 miR-155-mediated downregulation of these targets may partly explain the leukemogeneic role of this oncomiR.
In Epstein-Barr virus-transformed B cells, miR-155 expression is regulated by NF-κB, 13 a transcription factor that is constitutively active in AML. 14 Recently, Gerloff et al. 11 reported that miR-155 transcription in AML is also regulated by NF-κB. The transcriptional activity of NF-κB is primarily regulated by physical interaction with inhibitory IκB proteins (IκBα and IκBβ), which prevents its nuclear translocation. IκB complex stability is regulated by signal-induced phosphorylation at residues Ser32 and Ser36, which results in its degradation and release of NF-κB complex into the nucleus, where it can transactivate its target genes. [15] [16] [17] Degradation of the IκBα subunit of IκB is mediated by the ubiquitin/proteasome system. Importantly, activity of the E3 ligase responsible for IκBα ubiquitination is controlled by neddylation. 18 The neddylation cascade begins with activation of the small ubiquitin-like molecule, NEDD8, by the NEDD8-activating enzyme (NAE). Subsequently, NEDD8 is conjugated onto Cullin-RING E3 ligases (CRLs), a class of ubiquitin ligases, which require neddylation for their activity. Neddylated CRLs polyubiquitinate their substrates, resulting in proteasomal degradation. 19 In addition to IκBα, CRL substrates include a number of other tumor suppressors, such as the cyclin-dependent kinase inhibitors p27 (ref. 20) and p21, 21 as well as CDT1 (DNA replication factor 1), 22 NRF2 (Nuclear factor (erythroid-derived) 23 and CHK1 (Check point kinase 1). 24 Neddylation can be selectively blocked by MLN4924. 25 In the presence of enzymatically active NAE, MLN4924 forms a stable MLN4924-NEDD8 adduct preventing NAE from further activation of NEDD8. 25 This terminates the pathway at an early step. In preclinical studies, MLN4924 has shown promising activity against diffuse large B-cell lymphoma and AML, correlating with inhibition of NF-κB activity. 26, 27 These data suggest that the inhibition of NF-κB is a key component of this compound's activity in AML; however, the effects of MLN4924 on key downstream targets of NF-κB remain poorly understood.
Given the role of miR-155 in promoting leukemogenesis and its regulation by NF-κB, which is partially controlled by neddylation, we hypothesized that MLN4924 would decrease miR-155 levels in AML cells and result in antileukemic effects. Importantly, MLN4924 is already being used in clinical trials for AML, 28 allowing the rapid translation of positive results to the clinic. Indeed, we found that MLN4924 decreased miR-155 expression through decreasing NF-κB binding to the miR-155 promoter. In turn, it restored expression of the miR-155 targets, SHIP1, PU.1 and the macrophage colony-stimulating factor receptor. MLN4924 treatment also triggered monocytic differentiation of human AML cells and prolonged survival of mice xenografted with human leukemic cells. Furthermore, the forced expression of miR-155 partially abrogated the effects of MLN4924, demonstrating that the inhibition of this miR is a critical component of its activity in AML.
MATERIALS AND METHODS
Cell culture and treatment AML cell lines MV4-11 (CRL-9591), THP-1 (TIB-202) Kasumi-1 (CRL-2724) and HEK-293T (CRL-11268) were from American Type Culture Collection (ATCC). MOLM-13 cells (ACC 554) were from German Collection of Microorganisms and Cell Cultures (DSMZ, Germany). CG-SH cells, 29 PU.1-null cell line (503) and its stable transfectant with PU.1-estrogen receptor α fusion (503/PUER) 30 were described. All AML lines were cultured in RPMI-1640, whereas HEK-293T cells were grown in DMEM, both media supplemented with 10% fetal bovine serum and 1% Antibiotic-Antimycotic (Gibco Inc., Grand Island, NY, USA). Cells were treated with MLN4924 (Millennium Pharmaceuticals Inc., Cambridge, MA, USA), or vehicle control (0.01% DMSO (dimethyl sulfoxide)) at concentrations indicated.
Primary AML samples
Blasts from AML patients were obtained from The Ohio State University (OSU) Leukemia Tissue Bank. All patient samples were selected based on high miR-155 expression and were FLT3-ITD+. All patients provided written informed consent in accordance with the Declaration of Helsinki under an Institutional Review Board approved protocol and according to OSU institutional guidelines for tissue collection and the use in research. Primary blasts were cultured in StemSpan SFEM medium (Stem Cell Technologies, Vancouver, BC, Canada), supplemented with 20% fetal bovine serum and StemSpan CC100 cytokine cocktail (Stem Cell Technologies). Blasts were treated with MLN4924 (Millennium Pharmaceuticals Inc.) at concentrations specified in the figure legends, or vehicle control (0.01% DMSO).
Mice
Female NSG (NOD/SCIDγ; Non-Obese Diabetic/Severe Combined Immunodeficient γ) mice were from Jackson Laboratories (Bar Harbor, ME, USA). The mice used were between 4 and 6 weeks of age. Animal studies followed the rules and regulations of the Institutional Animal Care and Use Committee at the Ohio State University.
MV4-11 xenograft mouse model
Spleen cells (3 × 10 5 ) from MV4-11-transplanted NSG mice were intravenously injected into secondary NSG recipient mice via tail vein. One week later, the engrafted mice received intraperitoneal treatments of 180 mg/kg every other day, consisting of a total of nine injections. Mice in the control group were treated similarly with the vehicle alone (20% 2-hydroxypropylbetacyclodextrin). Peripheral blood was collected 24 and 48 h post first injection to measure the expression of pri-miR-155 and mature miR-155. Mononuclear cells, spleen, sternum, liver and kidney were collected from mice 21 days after the first injection and analyzed for white blood cell count and hematoxylin-eosin staining of tissues. For the survival study, the leukemic mice were treated with MLN4924 180 mg/kg, or vehicle two weeks after MV4-11 cell transplantation every other day for 21 days and followed longitudinally for disease progression and survival.
Statistical analysis
Data were represented as mean ± s.d. and analyzed using the two-tailed Student's t-test. The mean and s.d. were calculated and displayed in bar graphs as the height and the corresponding error bar, respectively. Mouse survival data were analyzed using the Kaplan-Meier and long-rank test methods (Graph Pad Prism, GraphPad Software, La Jolla, CA, USA). A Po0.05 was considered statistically significant (*Po0.05, **Po0.01 and ***Po0.001). 
Other methods

RESULTS
Antileukemic effects of inhibiting miR-155 expression in AML cells
High expression of miR-155 is associated with FLT3-ITD mutations and correlates with poor prognosis in AML. 4, 5, 31 MOLM-13 and MV4-11 AML cells harbor FLT3-ITD and express relatively high levels of miR-155 ( Supplementary Figures S1A and B ). Using transferrin-conjugated nanoparticles (Tf-NP), 32 we delivered antagomiR-155, or a scramble control to these cells. The transferrin (Tf) receptor is generally expressed on AML cells, thereby facilitating Tf-NP uptake via Tf receptor-mediated endocytosis. Forty-eight hours after Tf-NP treatment, MV4-11 cells receiving antagomiR-155 had a fivefold decrease in mature miR-155 levels compared with cells receiving a scramble control ( Figure 1a ). This was paralleled by an increase in SHIP1 protein (a direct miR-155 target) and cleaved caspase-3 (Figure 1b ), indicating the onset of apoptosis. AntagomiR-155 treatment also resulted in a threefold reduction in the number of colonies relative to control in MV4-11 cells treated with Tf-NPs, plated in methylcellulose and scored 7 days later ( Figure 1c ). Similar results were obtained in primary blasts expressing high levels of miR-155 ( Figure 1d and Supplementary Figure S2 , 300 or 500 nM MLN4924 (as indicated above the lanes) for 12 h were used in EMSA with radiolabeled probes containing NF-κBbinding sites from human miR-155 promoter (κ1 and κ2). NF-κB/DNA complexes are indicated by a black arrowhead. Specificity of binding is shown by using antibodies against the NF-κB subunits, p65 and p50, to supershift the DNA-protein complexes (marked with white arrowhead; SS) and competition with unlabeled oligos containing either the Igκ gene-derived NF-κB site (IgκB), or unrelated C/EBP-binding site. Free probe (FP) is indicated. (b) Chromatin immunoprecipitation using MV4-11 cells treated with 300 or 500 nM MLN4924 for 12 h. DMSO treatment served as a control (veh). Relative percent enrichment over input was measured by real-time PCR with specific primers covering the miR-155 promoter region containing the two NF-κB-binding sites (κ1 on the left and κ2 on the right). An average of three measurements is shown. Triplicate readings were averaged and error bars indicate s.d. (c) 293T cells were stimulated with 10ng/ml PMA for 2 h to activate NF-κB and then treated with either DMSO (veh), or MLN4924 (100 and 300 nM) for an additional 6 h, followed by transient transfection with firefly luciferase vectors driven by the miR-155 promoter, either wild type (WT) or with both NF-κB sites mutated (mut κB1/mut κB2) together with TK-promoter-driven Renilla luciferase vector. Cell lysates were analyzed for luciferase activity.
sought for clinically available compounds that could interfere with the expression of this oncomiR. We first confirmed that the miR-155 promoter is positively regulated by the NF-κB transcription factor. 11, 13 Using EMSA with an oligonucleotide containing the canonical NF-κB site, we found that NF-κB constitutively binds to this element in nuclear extracts from MV4-11 cells (Supplementary Figure S3A , lane 2). Co-incubation with antibodies against the p65 and p50 subunits of NF-κB resulted in supershifted complexes, confirming NF-κB binding in this assay (Supplementary Figure S3A, lanes 3 and 4) . A neddylation inhibitor with antineoplastic activity, MLN4924, has been developed 33 and is being tested in clinical trials. 28, 33, 34 One of the downstream effects of MLN4924 is the inhibition of NF-κB activity. 26, 27 Consistent with a previous report, 27 we showed that DNA binding of NF-κB was strongly inhibited by treatment of MV4-11 cells with 500 nM MLN4924 (Supplementary Figure S3A , lane 5), which had no effect on the levels of p65/NF-κB (Supplementary Figure S3B ). We also observed that the treatment of cell lines (Supplementary Figure S4A ) and primary blasts carrying FLT3-ITD mutations (Supplementary Figure S4B) with MLN4924 in the nanomolar range (100-1000 nM), resulted in a time-and concentration-dependent decrease in cell proliferation ( Supplementary Figures S4A and B ; Supplementary Table S2 ) and induction of apoptosis (Supplementary Figure S4C) .
Thus, we hypothesized that MLN4924 decreases the expression of miR-155 in AML through the inhibition of NFκB. To test this, MV4-11 cells were cultured in 100-500 nM MLN4924 and miR-155 levels were determined by quantitative real-time reverse transcription-PCR. MLN4924 treatment resulted in a significant downregulation of miR-155 expression specifically in FLT3-ITD cells in a dose- ( Figure S2 ).
MLN4924 disrupts binding of NF-κB to the miR-155 promoter From a mechanistic standpoint, we confirmed that treatment with MLN4924 caused extensive inhibition of NAE (measured by the levels of neddylated cullins; Supplementary Figure S5A ), and cytoplasmic accumulation of the known CRL substrate, pSer32-I-κBα (Supplementary Figure S5A) . Accumulation of the active I-κBα (phosphorylated on Ser32) is expected to retain the active p65/p50 heterodimer of NF-κB in the cytoplasm, preventing its nuclear translocation, and thus diminishing NF-κB-dependent transcription. Indeed, we observed a decrease in nuclear localization of p65 in MV4-11 cells treated with MLN4924 (Supplementary Figure S5B ), which correlated with a decrease in NF-κB transcriptional activity (Supplementary Figure 5C ), similar to that achieved with siRNAs against the p65/NF-κB.
Two NF-κB-binding sites on the miR-155 promoter were previously identified in Epstein-Barr virus-positive B cells. 13 To verify that NF-κB also binds to the miR-155 promoter in AML cells, we used EMSA with nuclear extracts from MV4-11 cells. We detected strong binding of the NF-κB complex to both NF-κB sites in vitro (κB1 and κB2; Figure 3a , lanes 2 and 12), which was significantly decreased after 12 h of treatment with 300 or 500 nM MLN4924 (Figure 3a, lanes 3, 4, 13 and 14 ). NF-κB binding to the miR-155 promoter was diminished by the addition of cold oligonucleotides containing the canonical NF-κB site (IgκB site; Figure 3a , lanes 5 and 15), but not by the ones containing an unrelated C/EBP-binding site (Figure 3a, lanes 6 and 16) . In addition, supershifting complexes were observed in the presence of anti-p50 and anti-p65 antibodies, but not with normal IgG, or c-Rel antibody (Figure 3a MV4-11 cells with 300 nM MLN4924 for 12 h led to over twofold inhibition of NF-κB enrichment on both binding sites of the miR-155 promoter (Figure 3b ; P o0.01).
To determine whether MLN4924-induced reduction in NF-κB binding to the miR-155 promoter results in decreased NF-κB transcriptional activity, we mutagenized both NF-κB sites in the Figure S6, lanes 4 and 8) . Next, we needed a system to measure the NF-κB-dependent transcriptional activity in response to MLN4924. Owing to low transfection efficiency of MV4-11 cells (30% using optimized nucleofection protocol; Lonza), we chose to transfect miR-155 promoter-luciferase constructs into 293T cells treated with phorbol myristate acetate (PMA), a known activator of the NF-κB pathway. As shown by EMSA ( Supplementary  Figure S7, lanes 3 and 9) , the exposure of 293T cells to 10 ng/ml of PMA for 2 h led to robust NF-κB DNA binding. Similar to the effect of MLN4924 in MV4-11 cells, addition of MLN4924 to PMAstimulated 293T cells strongly diminished NF-κB DNA binding to the miR-155 promoter ( Supplementary Figure S7, lanes 6 and 12) , and miR-155 promoter-driven luciferase activity (Figure 3c) . In contrast, a miR-155 promoter with both NF-κB sites mutated was less effective in driving luciferase activity and unaffected by MLN4924 treatment (Figure 3c ). These findings demonstrate that MLN4924 decreases binding of NF-κB to the miR-155 promoter and NF-κB-dependent transcriptional activity, leading to the downregulation of miR-155 expression.
MLN4924 treatment results in upregulation of the miR-155 target, SHIP1 and inhibition of the PI3K/AKT pathway in AML cells
The tumor suppressor SHIP1 is a direct target of miR-155, and its knockdown in hematopoietic cells, similar to the overexpression of miR-155, can result in a myeloproliferative phenotype, or a preleukemic pre-B-cell proliferation followed by B-cell malignancy. 6, 7, 9, 35 Thus, we hypothesized that MLN4924-induced decrease in miR-155 expression might also result in derepression of SHIP1 expression. To test this, levels of SHIP1 mRNA and protein were assessed in MLN4924-treated AML cells. Upon 24 h of treatment with concentrations of MLN4924 near the IC 50 , SHIP1 mRNA increased ninefold in MV4-11 cells (P o0.01), and 2-2.5-fold in samples from two patients with high levels of miR-155 (P o 0.05; Figure 4a ). SHIP1 protein was also upregulated in all samples, as shown by the western blot (Figure 4a ). SHIP1 functions by hydrolyzing the 5ʹ phosphate of phosphatidylinositol (3,4,5)-triphosphate to generate phosphatidylinositol (3,4)-bisphosphate. This blocks the PI3K-mediated membrane localization of Pleckstrin homology domain-containing signaling molecules, such as AKT and PLCγ, which have critical regulatory roles in diverse cellular processes. Overexpression of miR-155 has been shown to activate the AKT pathway via the downregulation of SHIP1 in natural killer cell lymphoma/leukemia. 36 Thus, we postulated that MLN4924-induced upregulation of SHIP1 would result in the downregulation of the PI3K/AKT pathway. As expected, AML cells treated with MLN4924 showed decreased levels of active phospho-AKT (Thr308) in both MV4-11 cells and primary AML patient blasts ( Figure 4b ) treated with MLN4924, as assessed by western blot.
In summary, decreased miR-155 expression by MLN4924 resulted in the reactivation of SHIP1 tumor suppressor expression and inhibition of active AKT.
MLN4924 induces monocytic differentiation of AML cells
It has been demonstrated that the introduction of miRNA-155 into CD34+ hematopoietic progenitor cells greatly reduced myeloid and erythroid colony formation, suggesting that miR-155 may inhibit myeloid differentiation. 8 In addition, miR-155 has been reported to directly target PU.1, 10,11,37 C/ EBPβ 7 and the M-CSF receptor, 38 key players in myelomonocytic differentiation. As MLN4924 decreases miR-155 expression in AML cells (Figure 2 ), we hypothesized that treatment with this compound might induce cell differentiation. To avoid rapid apoptosis, we tested MV4-11 cells using relatively low concentrations of MLN4924. Cells were cultured in the presence of 20, 50 or 100 nM MLN4924, or 0.01% DMSO and monitored daily for morphological changes by Wright-Giemsa staining of cytospins. On day 6, MV4-11 cells acquired monocytic morphology at every tested concentration of MLN4924 (Figure 5a ) and a decreased clonogenic ability (Figure 5b ). Furthermore, cell surface staining and flow cytometric analyses indicated a dose-responsive increase in monocytic markers, CD14+ and CD115+ (macrophage colony-stimulating factor receptor; Figure 5c ). We also observed an increase in myeloid maturation markers, CD11b+ and CD11c+, and a modest decrease in CD33 expression (Supplementary Figure S8 ). Finally, treatment with MLN4924 strongly inhibited the expression of c-myc protein (Figure 5d ), a critical event for allowing early myeloid precursors to enter a differentiation pathway. 39 We confirmed these findings in primary cells. Blasts from patient 1 were treated with 20, 50 and 100 nM MLN4924 for up to 6 days. Wright-Giemsa-stained cytospins revealed an increase in cells with monocyte/macrophage morphology even at concentrations as low as 20 nM (Figure 5e ). Phenotypically, 50 and 100 nM concentrations led to a decrease in the CD33+ population, as well as an increase in CD14+, CD115+, CD11b+, CD11c+ and CD36+ populations (Figure 5f ; Supplementary Table  S3 ). MLN4924-induced differentiation of AML cells prompted us to investigate the expression of PU.1, a transcription factor indispensable for myeloid differentiation 12 and a direct target of miR-155. 10 Indeed, exposure to 100 nM MLN4924 for as little as 24 h resulted in a 22-fold increase in PU.1 protein expression in MV4-11 cells (Figure 5g ; top panel) and a threefold increase in PU.1 protein expression in patient blasts (Figure 5g ; bottom panel).
We wondered if a short-term treatment with MLN4924 would be sufficient to set the differentiation program in motion. MV4-11 cells were treated with 100 nM MLN4924 for 24 h, washed three times and cultured in medium without MLN4924 for up to six additional days (diagrammed on top of Figure 6a ). Monocytic morphology was observed as early as day 6 of the experiment (days 1+5; Figure 6a ). Downregulation of c-myc protein (Figure 6b ) and upregulation of CD115 and CD11c were also noted ( Figure 6c ). Interestingly, the activity of MLN4924 appears to require at least low levels of PU.1, as this compound had no effect on growth or morphological differentiation of a PU.1-null cell line ( Supplementary Figures S9A and B) . However, MLN4924 treatment of a PU.1 inducible stable transfectant, which expressed low levels of PU.1 protein in the nucleus even in the absence of the inducer (Supplementary Figure S9C) , caused growth inhibition and morphological changes consistent with differentiation ( Supplementary Figures S9A and B) .
In summary, our data show that low concentrations of MLN4924 can induce differentiation of AML cells. Importantly, a transient exposure of MV4-11 cells to MLN4924 is sufficient to induce monocytic differentiation, suggesting that MLN4924 can activate a molecular switch promoting differentiation of leukemic blasts.
Ectopic expression of miR-155 interferes with MLN4924-mediated antileukemic effects
Our results suggested that the downregulation of miR-155 by MLN4924 might be at least partially responsible for the compound's activity in AML. Thus, we hypothesized that MLN4924's activity would be abrogated by miR-155 overexpression in AML cells. We transfected AML blasts from patient 3 (Pat. 3) with miR-155 precursor and 24 h later treated them with 500 nM MLN4924, or vehicle for an additional 48 h. As compared with the scramble miRNA control, mature miR-155 expression in primary blasts transfected with miR-155 precursor was approximately 50-fold higher (Figure 7a ) and ectopic expression of miR-155 significantly reduced the impact of MLN4924 on cell viability (almost twofold; P = 0.02; Figure 7b ). As expected, the 24-h treatment of scramble miR-transfected cells with 500 nM MLN4924 resulted in the upregulation of known direct targets of miR-155, SHIP1 and PU.1 proteins (Figure 7c ), as well as induction of apoptosis, determined by annexin V staining (Figure 7d ). In contrast, the overexpression of miR-155 partially prevented the induction of SHIP1 and PU.1 proteins, as well as the impact of MLN4924 on apoptosis (Figures 7c and d) .
These findings support the notion that MLN4924-induced downregulation of miR-155 is a component of its antileukemic activity.
In vivo activity of MLN4924
To test the activity of MLN4924 in AML in vivo, a human AML xenograft model was used. NOD/SCIDγ mice were inoculated via tail vein with MV4-11 AML cells. Upon engraftment, leukemic cells were harvested from the spleens and injected intravenously into secondary recipients. One week later, mice were injected intraperitoneally with 180 mg/kg of MLN4924 (n = 10), or vehicle control (n = 10) three times a week. As early as 24 and 48 h after the first dose of MLN4924, primiR and mature miR-155 expression levels in the peripheral blood of transplanted mice were decreased (by 50% at 24 h and by 80% at 48 h; P o0.01; Figure 8a ). Twenty-one days following the first dose of treatment, three mice representing each group were killed and analyzed (Figures 8b-d) . The average white blood cell count was lower in the MLN4924-treated group (5333 cells/μl ± 1040) compared with the vehicle-treated group (36 166 cells/μl ± 10 598; P o 0.01; Figure 8b ). In addition, the average spleen weight was reduced in the MLN4924-treated group compared with the control group (58.06 mg ± 12.74 vs 305.66 mg ± 51.1; P o 0.01, Figure 8c ). Hematoxylin and eosin staining was performed on sections from spleen, sternum and liver of xenografted mice (Figure 8d ). MLN4924-treated mice showed decreased infiltration of blasts in the sternum, spleen, liver and kidney, as compared with the control animals ( Figure 8d ). Also, MLN4924 significantly prolonged the survival of leukemic mice (Figure 8e ). The median survival was 46 vs 31 days for the MLN4924-treated group vs vehicle-treated group (P o 0.0001, Log-Rank test, n = 10 per group; Figure 8e ), respectively. These data demonstrate that MLN4924 treatment in vivo results in decreased miR-155 expression and significant antileukemic activity.
DISCUSSION
The expression of miR-155 is low in normal hematopoietic cells and often upregulated in AML, where it likely mediates aberrant cell differentiation and proliferation. 11, 40 Recently, we found that high miR-155 expression is an independent predictor of adverse prognosis in cytogenetically normal AML patients. 4 Thus, therapeutic silencing of this microRNA might represent a novel strategy to treat aggressive AML. One approach may eventually involve the use of the antagomiR technology; 41 for an immediate strategy that would allow us to inhibit aberrant miR-155 expression in malignant blasts by pharmacological intervention.
We reasoned that to identify a clinically available miR-155 inhibitor, the first logical step was to understand the mechanisms leading to its dysregulation. As NF-κB transcriptionally regulates miR-155 in B cells, 13, 42 we postulated that it may do the same in AML and that pharmacological inhibition of NF-κB might be a potentially successful approach to downregulate miR-155 expression in AML. Among the compounds that are already in clinical trials and inhibit NF-κB, 26, 27, 43 we selected MLN4924 because of its promising activity in AML and minimal toxicity to normal cells. 27 We demonstrate that indeed MLN4924 decreases NF-κB binding to the miR-155 promoter, resulting in the downregulation of miR-155 expression, upregulation of several of its key target genes and ultimately in antileukemic activity, which we demonstrated to be mediated by miR-155 downregulation. As a neddylation inhibitor, MLN4924 is likely to act on multiple pathways; however, our data support a preferential antileukemia activity in high miR-155-expressing cells.
As expected, pharmacological downregulation of miR-155 by MLN4924 led to the upregulation of SHIP1 and PU.1, key targets of miR-155 whose aberrant expression contributes to blasts' proliferation and differentiation block. 7, [9] [10] [11] SHIP1 is a tumor suppressor 37, 44 involved in the regulation of the PI3K/AKT pathway, which is often abnormally activated in cancer and AML. 45 Previous reports showed that aberrant expression of miR-155 in natural killer cells induces dysregulation of the SHIP1/AKT signaling pathway by decreasing SHIP1 protein expression. 36 Furthermore, miR-155 overexpression and knockout of SHIP1 exhibit similar myeloproliferative phenotypes in mice. 6, 9 This suggests that SHIP1 suppression is a key contributor to miR-155-associated leukemia. Consistent with our hypothesis, we found that SHIP1 was strongly upregulated by MLN4924 in a miR-155-dependent manner, concomitant with the downregulation of the PI3K/AKT pathway. In addition, we demonstrate that MLN4924 also mediates monocyte/macrophage differentiation of AML cells. This effect is likely facilitated by the upregulation of PU.1, a transcription factor important for maturation of myeloid cells and a known target of miR-155. [10] [11] [12] Indeed, our results showed that MLN4924-dependent inhibition of miR-155 expression led to the upregulation of PU.1 protein, whereas ectopic expression of miR-155 in AML blasts correlated with lower levels of PU.1 protein. Upon MLN4924 treatment, we also observed an increase of the surface expression of macrophage colonystimulating factor receptor, a marker of monocytic differentiation 46 that is transcriptionally regulated by PU.1 47 and has been recently demonstrated to be one of the miR-155 targets. 10 Interestingly, even a transient (that is, ⩽ 24 h) exposure to a relatively low MLN4924 concentration, led to re-expression of PU.1 and was sufficient for the onset of monocytic differentiation. This result is analogous to findings that short-term induction of expression of another master regulator of myelopoiesis, C/EBPα, in myeloid progenitor cells was also sufficient for the inception of granulocytic maturation. 48 MLN4924 treatment appears to have a preferential activity on cells harboring FLT3-ITD and in turn expressing higher miR-155 levels (Supplementary Figure S4) . Likely, this may be related to a biologic dependence of these leukemic cells on high miR-155 expression. Altogether, our data support the idea that pharmacologic targeting of miR-155 may represent a novel therapeutic approach in high-risk AML. Changing levels of this oncomiR seemingly affects a cascade of concurrently active leukemiapromoting mechanisms that dysregulate hematopoietic cell growth, differentiation and survival. Thus, in addition to a possible use of this drug as a single agent in AML patients not candidates for intensive chemotherapy induction, our findings also provide support for the use of MLN4924 in combination with chemotherapy, as knocking down high miR-155 levels may ultimately restore chemosensitivity in otherwise resistant AML blasts. 4 Over the past decades, efforts have been made to develop antileukemic small-molecule inhibitors with high biologic activity and low toxicity, specifically targeting leukemogenic proteins, including FLT3-ITD, which was shown to contribute to pharmacological downregulation of miR-155. 11 However, AML patients often demonstrate primary 49 or secondary 50,51 resistance to these inhibitors. More recently, miR-155 has been shown itself to activate the NF-κB signaling pathway; 52 thus, downregulation of miR-155 by MLN4924 could provide an additional mechanism that potentiates a primary effect of MLN4924 on NF-κB in a NEDD8independent manner. Given promising anticancer activity of MLN4924 in preclinical models of AML and solid tumors, 27, 33, 53, 54 a recent study was designed to determine whether and how resistance might occur. It was demonstrated that heterozygous mutations in NAEβ can occur in cell lines and xenograft models exposed to high concentrations of MLN4924, thus reducing this compound's potency. 54 However, MLN4924-resistant mutations in NAEβ have not been described in human subjects. Our data showing monocytic differentiation of AML cells using transient, lower dosing of MLN4924 may decrease the chance of developing resistance to this compound.
In summary, we demonstrate for the first time the promise of targeting miR-155 in AML by an investigational drug, MLN4924. We anticipate that our discovery will better inform how to use this agent and select the most responsive patients, thereby leading to novel therapeutic strategies and eventually better outcomes for AML patients.
